Avalo Therapeutics Inc Cash Flow Conversion Efficiency
Avalo Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Avalo Therapeutics Inc (AVTX) has a cash flow conversion efficiency ratio of -0.179x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.36 Million) by net assets ($91.55 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Avalo Therapeutics Inc (2012–2024)
Cash flow conversion efficiency of Avalo Therapeutics Inc from 2012 to 2024. This chart illustrates how Avalo Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Avalo Therapeutics Inc (AVTX) stock price for real-time trading data and today's change.
Avalo Therapeutics Inc Cash Flow Conversion Ratio Explained
Avalo Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Avalo Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Avalo Therapeutics Inc ranked by their cash flow conversion efficiency. Also see AVTX stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Acusensus Ltd
AU:ACE
|
0.023x |
|
DEEZER S.A. EO 1
F:L0A
|
N/A |
|
Hyundai Pharm
KO:004310
|
0.019x |
|
Hawesko Holding AG
XETRA:HAW
|
0.022x |
|
Blue Water Acquisition Corp. IV
NYSE:BWIV
|
0.350x |
|
Dynacons Systems & Solutions Limited
NSE:DSSL
|
0.031x |
|
Ekovest Bhd
KLSE:8877
|
0.159x |
|
Baiksan
KO:035150
|
0.040x |
Annual Cash Flow Conversion Efficiency for Avalo Therapeutics Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Avalo Therapeutics Inc from 2012 to 2024. Review free cash flow generation of Avalo Therapeutics Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $133.03 Million | $-49.06 Million | -0.369x | +91.22% |
| 2023-12-31 | $7.30 Million | $-30.68 Million | -4.200x | -271.39% |
| 2022-12-31 | $-10.91 Million | $-26.75 Million | 2.451x | +179.80% |
| 2021-12-31 | $23.08 Million | $-70.89 Million | -3.071x | -86.09% |
| 2020-12-31 | $24.56 Million | $-40.54 Million | -1.650x | -81.10% |
| 2019-12-31 | $21.00 Million | $-19.13 Million | -0.911x | -509.13% |
| 2018-12-31 | $20.91 Million | $-3.13 Million | -0.150x | -133.29% |
| 2017-12-31 | $27.86 Million | $12.52 Million | 0.449x | +100.64% |
| 2016-12-31 | $207.00K | $-14.57 Million | -70.402x | -8963.27% |
| 2015-12-31 | $13.08 Million | $-10.16 Million | -0.777x | -231.80% |
| 2014-12-31 | $-26.33 Million | $-15.52 Million | 0.589x | -8.42% |
| 2013-12-31 | $-17.85 Million | $-11.49 Million | 0.644x | +158.73% |
| 2012-12-31 | $8.48 Million | $-9.29 Million | -1.096x | -- |
About Avalo Therapeutics Inc
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its nam… Read more